Migraine and Patent Foramen Ovale: Is Platelet Hyperactivity the Underlying Mechanism?
- PMID: 35818508
- PMCID: PMC9270590
- DOI: 10.1016/j.jacbts.2022.04.001
Migraine and Patent Foramen Ovale: Is Platelet Hyperactivity the Underlying Mechanism?
Keywords: migraine with aura; oxidative stress; patent foramen oval; platelets; tissue factor.
Conflict of interest statement
Dr Sommer has a relationship with W.L. Gore & Associates; is the National Cardiology primary investigator on the Gore RELIEF clinical study; was the national coprimary investigator on the ASSURED study; and is currently an investigator in the REDUCE-PAS study. W.L. Gore & Associates provides institutional funding to Columbia University. Dr Robbins has reported that she has no relationships relevant to the contents of this paper to disclose.
Comment on
- doi: 10.1016/j.jacbts.2022.02.002
References
-
- Bagasse de Dham O. Migraines are a serious problem. Employers can help. Harvard Business Review. February 24, 2021. https://hbr.org/2021/02/migraines-are-a-serious-problem-employers-can-help Accessed April 19, 2022.
-
- Sommer R.J., Nazify T., Privier L., Robbins B.T. Retrospective review of thienopyridine therapy in migraineurs with patent foramen oval. Neurology. 2018;91(22):1002–1009. - PubMed
-
- GORE CARDIOFORM septal occlude migraine clinical study (RELIEF) U.S. National Library of Medicine. https://www.clinicaltrials.gov/ct2/show/NCT04100135?term=RELIEF&cond=Mig... Accessed April 19, 2022.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous